Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Bio-Rad Acquires GnuBIO and Fast Integrated DNA Sequencing Platform

By LabMedica International staff writers
Posted on 20 Apr 2014
Global life science and clinical diagnostics company Bio-Rad Laboratories, Inc. More...
(Hercules, CA, USA) has purchased GnuBIO, Inc. (Cambridge, MA. USA), a privately-held company that has developed a novel droplet-based DNA sequencing technology and a system that incorporates all DNA sequencing functions into a single, integrated workflow for medical diagnostics as well as research markets.

While other sequencing technologies require separate workflows for target selection, DNA amplification, DNA sequencing, and analysis, GnuBIO's technology integrates the entire workflow into a single, low-cost solution that produces results within hours, versus days.

GnuBIO's innovative system utilizes microfluidic and emulsion technology to perform complex, multiplexed reactions in droplets. The platform integrates the entire sample preparation workflow on a chip, from sample capture, PCR, and sequencing, to informatics. This capability offers a “Sample In, Answer Out” solution for performing more complete workflows whereby a clinical lab technician or a researcher simply loads genomic DNA into the cartridge and presses a button to start the run, with results delivered within hours.

“Bio-Rad’s leading positions in the clinical IVD market as well as the Droplet Digital PCR space make Bio-Rad the ideal acquisition partner for us,” said John Boyce, president, CEO, and founder of GnuBIO. “Bio-Rad’s reputation as well as its presence in both the clinical and research markets will be essential elements to the success of the GnuBIO platform. We are very excited to join the Bio-Rad family,” Mr. Boyce added. With this acquisition, Bio-Rad will expand its Digital Biology Center and establish a research and development site in Cambridge (MA, USA).

"We are pleased to have GnuBIO join Bio-Rad," said Norman Schwartz, Bio-Rad President and CEO; "We believe GnuBIO's innovative DNA workflow is well-suited for the clinical diagnostics sequencing market and will leverage Bio-Rad's leadership role in the area of droplet digital PCR."

Related Links:

Bio-Rad Laboratories
GnuBIO 



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: New findings show unique pathogen‑directed antibody patterns are already present years ahead of a formal diagnosis of inflammatory bowel disease (Image Credit: iStock)

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.